411 related articles for article (PubMed ID: 31614001)
21. Results of a Prospective Phase 2 Pilot Trial of
Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
[TBL] [Abstract][Full Text] [Related]
22. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
Michalski K; Mix M; Meyer PT; Ruf J
Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
[TBL] [Abstract][Full Text] [Related]
23.
Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
[TBL] [Abstract][Full Text] [Related]
24. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS;
Lancet Oncol; 2022 Nov; 23(11):1389-1397. PubMed ID: 36261050
[TBL] [Abstract][Full Text] [Related]
25. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
26. A prospective study on the early evaluation of response to androgen receptor-targeted agents with
Mollica V; Marchetti A; Fraccascia N; Nanni C; Tabacchi E; Malizia C; Argalia G; Rosellini M; Tassinari E; Paccapelo A; Fanti S; Massari F
ESMO Open; 2024 May; 9(5):103448. PubMed ID: 38718704
[TBL] [Abstract][Full Text] [Related]
27. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
28. Using
Denis CS; Cousin F; Laere B; Hustinx R; Sautois BR; Withofs N
J Nucl Med; 2022 Dec; 63(12):1815-1821. PubMed ID: 35450960
[TBL] [Abstract][Full Text] [Related]
29.
Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539
[TBL] [Abstract][Full Text] [Related]
30. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
Shagera QA; Karfis I; Kristanto P; Spyridon S; Diamand R; Santapau A; Peltier A; Roumeguère T; Flamen P; Artigas C
J Nucl Med; 2023 Dec; 64(12):1869-1875. PubMed ID: 37770114
[TBL] [Abstract][Full Text] [Related]
31. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
32. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
33. The
Maffey-Steffan J; Scarpa L; Svirydenka A; Nilica B; Mair C; Buxbaum S; Bektic J; von Guggenberg E; Uprimny C; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):695-712. PubMed ID: 31776632
[TBL] [Abstract][Full Text] [Related]
34.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
35. Role of volumetric parameters obtained from
Güzel Y; Kömek H; Can C; Kaplan İ; Akdeniz N; Kepenek F; Gündoğan C
Ann Nucl Med; 2023 Sep; 37(9):517-527. PubMed ID: 37332068
[TBL] [Abstract][Full Text] [Related]
36. Prospective Comparison of
Duan H; Song H; Davidzon GA; Moradi F; Liang T; Loening A; Vasanawala S; Iagaru A
J Nucl Med; 2024 Jun; 65(6):897-903. PubMed ID: 38664016
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
38. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
[TBL] [Abstract][Full Text] [Related]
39. Pre-treatment
Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
[TBL] [Abstract][Full Text] [Related]
40.
John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L
J Nucl Med; 2023 Mar; 64(3):410-415. PubMed ID: 36215568
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]